



Figures - Key Numbers

Ticker: (NASDAQ: PIRS)
 Share price: \$2.73 (as of 3/17/17)
 Market Cap: \$117.55M (as of 3/17/2017)
 Revenue: \$3.1M
 (nine months ended Sept 30, 2016)
 Net Loss: \$16.2M
 (nine months ended Sept 30, 2016)
 Cash: \$36.6M (as of 09/30/2016)

Corporate Headquarters

Pieris Pharmaceuticals, Inc.
 255 State Street, 9th floor
 Boston, MA 02109
 +1 (857) 246 8998

Munich Site

Pieris Pharmaceuticals
 GmbH
 Lise-Meitner-Strasse 30
 85354 Freising
 Germany
 +49 (0) 8161 1411 400

For more information:

info@pieris.com

www.pieris.com

For business development or partnering inquiries, please contact Eckhard Niemeier, VP BD: niemeier@pieris.com

For investor relations inquiries, please contact Thomas Hoffman at The Trout Group, LLC: thoffman@troutgroup.com

Company Overview


Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin®-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics (tumor-targeted costimulatory approach and dual-checkpoint inhibitors), an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is registered trademark of Pieris.

Pieris Strategy

- Advance its lead IO program, PRS-343 (HER2/4-1BB), into clinical trials in H1 2017 and further develop its immuno-oncology franchise
- Advance its lead Asthma program PRS-060 (IL4Ra) into clinical trials in 2017 and strengthen its respiratory franchise for inhaled biologics
- Advance its anemia program PRS-080 (hepcidin) through first-in patient trials in 2017
- Continue to exploit its platform through new and existing partnerships

Anticalin Proteins

Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can bind to virtually any target of interest.



Differentiation from Antibodies

- Formatting flexibility for multispecific drugs
- Alternative delivery routes (e.g. inhaled)
- Cheaper, bacterial expression
- Tunable kinetics to match biological need
- Dominant patent position and positive FTO position

Management Team

Stephen S. Yoder, President & Chief Executive Officer
 Louis Matis, MD, SVP & Chief Development Officer
 Lance Thibault, Acting Chief Financial Officer
 Claude Knopf, SVP & Chief Business Officer
 Shane Olwill, PhD, VP, Development & Head of Immuno-Oncology
 Christine Rothe, PhD, VP, Head of Discovery & Alliance Management
 Mary Fitzgerald, PhD, VP, Respiratory Medicine
 Eckhard Niemeier, VP, Business Development
 Claus Schalper, VP, Finance

Board of Directors

Chau Khuong (Private Equity Partner, OrbiMed Advisors), Chairman
 Jean-Pierre Bizzari, MD (Former EVP, Celgene)
 Steven Prelack (SVP & COO, VetCor)
 Michael Richman (CEO, NextCure)
 Julian Adams, Ph.D (Former President of R&D, Infinity Pharma)
 Christopher Kiritsy (President, Arisaph Pharmaceuticals)
 Stephen S. Yoder (President & CEO, Pieris)



January 2017: Multi-program co-development immuno-oncology alliance. Includes PRS-332 and 4 additional programs



February 2017: Option on anemia program PRS-080 in Japan and other Asian countries



December 2015: Discovery and development of Anticalin therapeutics in immuno-oncology



October 2013: Co-development of novel Anticalin therapeutics, including cMet



Daiichi-Sankyo

April 2011: Discovery and development partnership on novel Anticalin therapeutics against two targets, including PCSK9



SANOFI

September 2010: Multi-target collaboration with both Sanofi and Sanofi Pasteur across a broad spectrum of indications

IMMUNO-ONCOLOGY PROGRAMS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND-enabling	Phase I	Phase Ib/IIa
PRS-343	4-1BB/HER2 Bispecific	IO		Worldwide					
PRS-342	4-1BB/GPC3 Bispecific	IO		Worldwide					
PRS-300s	n.d.	IO		Worldwide					
PRS-332	PD-1/n.d. Bispecific	IO		U.S.					
Servier 4 Programs	n.d./n.d. Bispecific	IO		U.S./ Milestones & Royalties					
Roche	n.d.	IO		Milestones & Royalties					

RESPIRATORY, ANEMIA AND OTHER DISEASE AREAS

Candidate	Target	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND-enabling	Phase I	Phase Ib/IIa
PRS-080	Hepcidin	Anemia		Major Markets ex-Japan					
PRS-060	IL4Ra	Asthma		Worldwide					
DS-9001	PCSK9	Dyslipidemia		Milestones & Royalties					
Daiichi Sankyo	n.d.	n.d.		Milestones & Royalties					
Sanofi	<i>P. aeruginosa</i>	Infectious disease		Milestones & Royalties					
PRS-110	cMet	Oncology		Major Markets					

Potential 2017 Milestones:

- Preclinical and clinical progression of ongoing programs
- First-in-Patient trial with PRS-343 (IO)
- First-in-Man trial for PRS-060 (asthma)
- Data from multispecifics IO platform
- First patient data for PRS-080 (anemia)
 - Phase 1b (single dose) in H1 2017
 - Phase 2a (multi-dose) in H2 2017
- Additional collaborations

Program Highlights

PRS-080 - Anemia

- Lead program against hepcidin
- Targets anemia in CKD and cancer
- Tuned kinetics to address target biology
- Phase 1b trial in CKD hemodialysis (HD) patients – dosing completed
- Phase 2a trial in CKD HD patients planned in H2 2017
- ASKA Pharmaceutical with option for Japan

PRS-060 – Respiratory Diseases

- Preclinical program against IL4Ra
- Targets asthma and other respiratory diseases
- Differentiates from antibodies against IL-4 and IL-13 through inhaled delivery directly into the lungs, contrasted with Q2W mAbs
- Local delivery is more convenient for patients and allows for very low doses, potentially resulting in a significant cost of goods advantage and expanded patient population over systemic mAbs

PRS-343 – (4-1BB/HER2 bispecific)

- Bispecific drug candidate with a 4-1BB-targeting Anticalin (key costimulatory target for tumor-specific T cells) and a HER2-targeting mAb (validated expression in bladder, gastric, breast cancer, etc.)
- PRS-343 has demonstrated strong tumor growth inhibition and lymphocyte infiltration *in vivo*, while avoiding undesirable peripheral T cell activation
- First-in-patient trial to start in first half of 2017

PRS-332 – (PD-1 / undisclosed checkpoint)

- Bispecific program combining an Anticalin against an undisclosed key checkpoint target with an anti-PD-1 mAb
- PRS-332 is being co-developed with Servier where Pieris retains full U.S. commercial rights

Pieris Immuno-Oncology Strategy

- Engage immune costimulatory targets in a highly novel, targeted manner with unique multispecifics, led by PRS-343
- Simultaneously block multiple immune checkpoints in one drug built on key backbone components (e.g. PD-1), led by PRS-332
- Demonstrate intra-pipeline synergy between targeted costimulatory engagement and multi-checkpoint blockade within own pipeline